149 related articles for article (PubMed ID: 33582655)
1. Clinical and genomic characteristics of metabolic syndrome in colorectal cancer.
Li Y; Zhao J; Wu X; Zhang Y; Jin Y; Cai W
Aging (Albany NY); 2021 Feb; 13(4):5442-5460. PubMed ID: 33582655
[TBL] [Abstract][Full Text] [Related]
2. Silencing of RHEB inhibits cell proliferation and promotes apoptosis in colorectal cancer cells via inhibition of the mTOR signaling pathway.
Tian Y; Shen L; Li F; Yang J; Wan X; Ouyang M
J Cell Physiol; 2020 Jan; 235(1):442-453. PubMed ID: 31332784
[TBL] [Abstract][Full Text] [Related]
3. The association of Metabolic Syndrome and its Components with the Incidence and Survival of Colorectal Cancer: A Systematic Review and Meta-analysis.
Han F; Wu G; Zhang S; Zhang J; Zhao Y; Xu J
Int J Biol Sci; 2021; 17(2):487-497. PubMed ID: 33613107
[No Abstract] [Full Text] [Related]
4. The combined effect of non-alcoholic fatty liver disease and metabolic syndrome on colorectal carcinoma mortality: a retrospective in Chinese females.
Chen ZF; Dong XL; Huang QK; Hong WD; Wu WZ; Wu JS; Pan S
World J Surg Oncol; 2018 Aug; 16(1):163. PubMed ID: 30097069
[TBL] [Abstract][Full Text] [Related]
5. Interaction of smoking and metabolic syndrome in increasing the recurrence risk of colorectal cancer in a Chinese male cohort: a retrospective study.
Chen DZ; Ji FY; Xu QM; Wu XX; Cai C; Zhang LJ; Li LJ
Sci Rep; 2018 Jan; 8(1):972. PubMed ID: 29343809
[TBL] [Abstract][Full Text] [Related]
6. Colorectal cancer and its association with the metabolic syndrome: a Malaysian multi-centric case-control study.
Ulaganathan V; Kandiah M; Zalilah MS; Faizal JA; Fijeraid H; Normayah K; Gooi BH; Othman R
Asian Pac J Cancer Prev; 2012; 13(8):3873-7. PubMed ID: 23098486
[TBL] [Abstract][Full Text] [Related]
7. Rab1A promotes proliferation and migration abilities via regulation of the HER2/AKT-independent mTOR/S6K1 pathway in colorectal cancer.
Cheng Z; Shao X; Xu M; Wang J; Kuai X; Zhang L; Wu J; Zhou C; Mao J
Oncol Rep; 2019 May; 41(5):2717-2728. PubMed ID: 30896866
[TBL] [Abstract][Full Text] [Related]
8. The metabolic syndrome and its components as prognostic factors in colorectal cancer: A meta-analysis and systematic review.
Lu B; Qian JM; Li JN
J Gastroenterol Hepatol; 2023 Feb; 38(2):187-196. PubMed ID: 36287138
[TBL] [Abstract][Full Text] [Related]
9. A five-immune-related genes-based prognostic signature for colorectal cancer.
Zhu L; Wang H; Wang Z
Int Immunopharmacol; 2020 Nov; 88():106866. PubMed ID: 32781411
[TBL] [Abstract][Full Text] [Related]
10. Association between metabolic syndrome and colorectal cancer incidence and all-cause mortality: a hospital-based observational study.
Chung KC; Juang SE; Chen HH; Cheng KC; Wu KL; Song LC; Lee KC
BMC Gastroenterol; 2022 Nov; 22(1):453. PubMed ID: 36368935
[TBL] [Abstract][Full Text] [Related]
11. Specific features of colorectal cancer in patients with metabolic syndrome: a matched case-control analysis of 772 patients.
Zarzavadjian Le Bian A; Denet C; Tabchouri N; Donatelli G; Wind P; Louvet C; Bennamoun M; Christidis C; Perniceni T; Fuks D; Gayet B
Langenbecks Arch Surg; 2018 Jun; 403(4):443-450. PubMed ID: 29704123
[TBL] [Abstract][Full Text] [Related]
12. Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer.
Cai Z; Ke J; He X; Yuan R; Chen Y; Wu X; Wang L; Wang J; Lan P; Wu X
Ann Surg Oncol; 2014 Jan; 21(1):179-88. PubMed ID: 23907312
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of Rab31 is associated with poor prognosis and promotes colorectal carcinoma proliferation via the mTOR/p70S6K/Cyclin D1 signalling pathway.
Yang L; Tian X; Chen X; Lin X; Tang C; Gao Y; Chen S; Ge Z
Life Sci; 2020 Sep; 257():118126. PubMed ID: 32707053
[TBL] [Abstract][Full Text] [Related]
14. The metabolic syndrome and its components as prognostic factors in metastatic colorectal cancer.
Reed M; Patrick C; Croft B; Walde N; Voutsadakis IA
Indian J Gastroenterol; 2019 Feb; 38(1):15-22. PubMed ID: 30701442
[TBL] [Abstract][Full Text] [Related]
15. DEPTOR expression negatively correlates with mTORC1 activity and tumor progression in colorectal cancer.
Lai EY; Chen ZG; Zhou X; Fan XR; Wang H; Lai PL; Su YC; Zhang BY; Bai XC; Li YF
Asian Pac J Cancer Prev; 2014; 15(11):4589-94. PubMed ID: 24969890
[TBL] [Abstract][Full Text] [Related]
16. Influence of IL1B, IL6 and IL10 gene variants and plasma fatty acid interaction on metabolic syndrome risk in a cross-sectional population-based study.
Maintinguer Norde M; Oki E; Ferreira Carioca AA; Teixeira Damasceno NR; Fisberg RM; Lobo Marchioni DM; Rogero MM
Clin Nutr; 2018 Apr; 37(2):659-666. PubMed ID: 28268030
[TBL] [Abstract][Full Text] [Related]
17. STK25-induced inhibition of aerobic glycolysis via GOLPH3-mTOR pathway suppresses cell proliferation in colorectal cancer.
Wu F; Gao P; Wu W; Wang Z; Yang J; Di J; Jiang B; Su X
J Exp Clin Cancer Res; 2018 Jul; 37(1):144. PubMed ID: 29996891
[TBL] [Abstract][Full Text] [Related]
18. Abdominal obesity, glucose intolerance and decreased high-density lipoprotein cholesterol as components of the metabolic syndrome are associated with the development of colorectal cancer.
Choi YJ; Lee DH; Han KD; Shin CM; Kim N
Eur J Epidemiol; 2018 Nov; 33(11):1077-1085. PubMed ID: 30196334
[TBL] [Abstract][Full Text] [Related]
19. The promise of mTOR inhibitors in the treatment of colorectal cancer.
Kim DD; Eng C
Expert Opin Investig Drugs; 2012 Dec; 21(12):1775-88. PubMed ID: 22978346
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity.
Jin ZZ; Wang W; Fang DL; Jin YJ
Biochem Biophys Res Commun; 2016 Sep; 478(4):1515-20. PubMed ID: 27565731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
